BRAF and melanoma: In the COMBI-AD trial, adjuvant dabrafenib-trametinib for 12 months in comparison to placebo improved RFS and DMFS in resected AJCCv7 stage III (sentinel lymph node (SLN) > 1 mm) melanoma with BRAF V600E/K mutations, although at the final analysis (>10 years of follow-up), the median OS was NR in either arm (p = 0.06), and in the subgroup analysis, the OS benefit was limited in patients with the V600K mutation [20].